1-19 of 19
Paul G. Richardson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma

Available to Purchase
Johannes M. Waldschmidt, Jake A. Kloeber, Praveen Anand, Julia Frede, Antonis Kokkalis, Valeriya Dimitrova, Sayalee Potdar, Monica S. Nair, Tushara Vijaykumar, Nam Gyu Im, Amy Guillaumet-Adkins, Nitish Chopra, Hannah Stuart, Lillian Budano, Noori Sotudeh, Guangwu Guo, Clemens Grassberger, Andrew J. Yee, Jacob P. Laubach, Paul G. Richardson, Kenneth C. Anderson, Noopur S. Raje, Birgit Knoechel, Jens G. Lohr
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6432–6444.
https://doi.org/10.1158/1078-0432.CCR-21-2040
Published: 01 December 2021
View articletitled, Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma
Open the PDF for Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

Available to Purchase
Irene M. Ghobrial, Chia-Jen Liu, Robert A. Redd, Raymond P. Perez, Rachid Baz, Oksana Zavidij, Romanos Sklavenitis-Pistofidis, Paul G. Richardson, Kenneth C. Anderson, Jacob Laubach, Patrick Henrick, Alexandra Savell, Kaitlen Reyes, Kalvis Hornburg, Stacey Chuma, Peter Sabbatini, Michael D. Robbins, Pamela S. Becker
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (2): 344–353.
https://doi.org/10.1158/1078-0432.CCR-19-0647
Published: 15 January 2020
View articletitled, A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma
Open the PDF for A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma

Free
Claire Fabre, Naoya Mimura, Kathryn Bobb, Sun-Young Kong, Güllü Gorgun, Diana Cirstea, Yiguo Hu, Jiro Minami, Hiroto Ohguchi, Jie Zhang, Jeffrey Meshulam, Ruben D. Carrasco, Yu-Tzu Tai, Paul G. Richardson, Teru Hideshima, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (9): 2938.
https://doi.org/10.1158/1078-0432.CCR-19-0959
Published: 01 May 2019
View articletitled, Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
Open the PDF for Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma in another window
Journal Articles

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

Free
Jacob P. Laubach, Chia-Jen Liu, Noopur S. Raje, Andrew J. Yee, Philippe Armand, Robert L. Schlossman, Jacalyn Rosenblatt, Jacquelyn Hedlund, Michael Martin, Craig Reynolds, Kenneth H. Shain, Ira Zackon, Laura Stampleman, Patrick Henrick, Bradley Rivotto, Kalvis T.V. Hornburg, Henry J. Dumke, Stacey Chuma, Alexandra Savell, Damian R. Handisides, Stew Kroll, Kenneth C. Anderson, Paul G. Richardson, Irene M. Ghobrial
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (2): 478–486.
https://doi.org/10.1158/1078-0432.CCR-18-1325
Published: 15 January 2019
View articletitled, A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
Open the PDF for A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma in another window
Journal Articles

Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma

Free
Noopur S. Raje, Edward A. Faber, Jr, Paul G. Richardson, Gary Schiller, Raymond J. Hohl, Adam D. Cohen, Andres Forero, Susan Carpenter, Tuan S. Nguyen, Ilaria Conti, Christopher J. Kaiser, Damien M. Cronier, James E. Wooldridge, Kenneth C. Anderson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (23): 5688–5695.
https://doi.org/10.1158/1078-0432.CCR-16-0201
Published: 30 November 2016
View articletitled, Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma
Open the PDF for Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution

Free
Min Tang, Rui Zhao, Helgi van de Velde, Jennifer G. Tross, Constantine Mitsiades, Suzanne Viselli, Rachel Neuwirth, Dixie-Lee Esseltine, Kenneth Anderson, Irene M. Ghobrial, Jesús F. San Miguel, Paul G. Richardson, Michael H. Tomasson, Franziska Michor
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16): 4206–4214.
https://doi.org/10.1158/1078-0432.CCR-15-2793
Published: 14 August 2016
View articletitled, Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution
Open the PDF for Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution in another window
Includes: Supplementary data
Journal Articles

Panobinostat for the Treatment of Multiple Myeloma

Free
Jacob P. Laubach, Philippe Moreau, Jesús F. San-Miguel, Paul G. Richardson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (21): 4767–4773.
https://doi.org/10.1158/1078-0432.CCR-15-0530
Published: 01 November 2015
View articletitled, Panobinostat for the Treatment of Multiple Myeloma
Open the PDF for Panobinostat for the Treatment of Multiple Myeloma in another window
Journal Articles

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

Free
Güllü Görgün, Mehmet K. Samur, Kristen B. Cowens, Steven Paula, Giada Bianchi, Julie E. Anderson, Randie E. White, Ahaana Singh, Hiroto Ohguchi, Rikio Suzuki, Shohei Kikuchi, Takeshi Harada, Teru Hideshima, Yu-Tzu Tai, Jacob P. Laubach, Noopur Raje, Florence Magrangeas, Stephane Minvielle, Herve Avet-Loiseau, Nikhil C. Munshi, David M. Dorfman, Paul G. Richardson, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (20): 4607–4618.
https://doi.org/10.1158/1078-0432.CCR-15-0200
Published: 14 October 2015
View articletitled, Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
Open the PDF for Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon

Free
Jacob P. Laubach, Paul G. Richardson
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2660–2662.
https://doi.org/10.1158/1078-0432.CCR-14-3190
Published: 14 June 2015
View articletitled, CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon
Open the PDF for CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon in another window
Journal Articles

Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy

Free
Chirayu G. Patel, Andrew J. Yee, Tyler A. Scullen, Neeharika Nemani, Loredana Santo, Paul G. Richardson, Jacob P. Laubach, Irene M. Ghobrial, Robert L. Schlossman, Nikhil C. Munshi, Kenneth C. Anderson, Noopur S. Raje
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (15): 3955–3961.
https://doi.org/10.1158/1078-0432.CCR-14-0434
Published: 31 July 2014
View articletitled, Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy
Open the PDF for Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy in another window
Journal Articles

Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma

Free
Claire Fabre, Naoya Mimura, Kathryn Bobb, Sun-Young Kong, Güllü Gorgun, Diana Cirstea, Yiguo Hu, Jiro Minami, Hiroto Ohguchi, Jie Zhang, Jeffrey Meshulam, Ruben D. Carrasco, Yu-Tzu Tai, Paul G. Richardson, Teru Hideshima, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4669–4681.
https://doi.org/10.1158/1078-0432.CCR-12-0779
Published: 30 August 2012
View articletitled, Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
Open the PDF for Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Treatment Options for Relapsed and Refractory Multiple Myeloma

Free
Sagar Lonial, Constantine S. Mitsiades, Paul G. Richardson
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (6): 1264–1277.
https://doi.org/10.1158/1078-0432.CCR-10-1805
Published: 15 March 2011
View articletitled, Treatment Options for Relapsed and Refractory Multiple Myeloma
Open the PDF for Treatment Options for Relapsed and Refractory Multiple Myeloma in another window
Journal Articles

Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma

Free
María Victoria Mateos, Maria Teresa Cibeira, Paul G. Richardson, Felipe Prosper, Albert Oriol, Javier de la Rubia, Juan José Lahuerta, Ramón García-Sanz, Sonia Extremera, Sergio Szyldergemajn, Claudia Corrado, Harald Singer, Constantine S. Mitsiades, Kenneth C. Anderson, Joan Bladé, Jesús San Miguel
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (12): 3260–3269.
https://doi.org/10.1158/1078-0432.CCR-10-0469
Published: 14 June 2010
View articletitled, Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma
Open the PDF for Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma in another window
Journal Articles

Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia

Free
Irene M. Ghobrial, Aldo Roccaro, Fangxin Hong, Edie Weller, Nancy Rubin, Renee Leduc, Meghan Rourke, Stacey Chuma, Antonio Sacco, Xiaoying Jia, Feda Azab, Abdel Kareem Azab, Scott Rodig, Diane Warren, Brianna Harris, Lyuba Varticovski, Peter Sportelli, Xavier Leleu, Kenneth C. Anderson, Paul G. Richardson
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (3): 1033–1041.
https://doi.org/10.1158/1078-0432.CCR-09-1837
Published: 01 February 2010
View articletitled, Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia
Open the PDF for Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia in another window
Journal Articles

Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib

Free
Melissa G. Ooi, Patrick J. Hayden, Vassiliki Kotoula, Douglas W. McMillin, Elpida Charalambous, Emily Daskalaki, Noopur S. Raje, Nikhil C. Munshi, Dharminder Chauhan, Teru Hideshima, Leutz Buon, Martin Clynes, Peter O'Gorman, Paul G. Richardson, Constantine S. Mitsiades, Kenneth C. Anderson, Nicholas Mitsiades
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (23): 7153–7160.
https://doi.org/10.1158/1078-0432.CCR-09-1071
Published: 30 November 2009
View articletitled, Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib
Open the PDF for Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib in another window
Includes: Supplementary data
Journal Articles

Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias

Free
Constantine S. Mitsiades, Cecile Rouleau, Cinara Echart, Krishna Menon, Beverly Teicher, Maria Distaso, Antonio Palumbo, Mario Boccadoro, Kenneth C. Anderson, Massimo Iacobelli, Paul G. Richardson
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (4): 1210–1221.
https://doi.org/10.1158/1078-0432.CCR-08-1270
Published: 19 February 2009
View articletitled, Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias
Open the PDF for Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias in another window
Includes: Supplementary data
Journal Articles

Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw

Free
Noopur Raje, Sook-Bin Woo, Karen Hande, Jeffrey T. Yap, Paul G. Richardson, Sonia Vallet, Nathaniel Treister, Teru Hideshima, Niall Sheehy, Shweta Chhetri, Brendan Connell, Wanling Xie, Yu-Tzu Tai, Agnieszka Szot-Barnes, Mei Tian, Robert L. Schlossman, Edie Weller, Nikhil C. Munshi, Annick D. Van Den Abbeele, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (8): 2387–2395.
https://doi.org/10.1158/1078-0432.CCR-07-1430
Published: 15 April 2008
View articletitled, Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw
Open the PDF for Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw in another window
Journal Articles

Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma

Free
S. Vincent Rajkumar, Paul G. Richardson, Martha Q. Lacy, Angela Dispenzieri, Philip R. Greipp, Thomas E. Witzig, Robert Schlossman, Carolyn F. Sidor, Kenneth C. Anderson, Morie A. Gertz
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (20): 6162–6167.
https://doi.org/10.1158/1078-0432.CCR-07-0807
Published: 18 October 2007
View articletitled, Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma
Open the PDF for Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma in another window
Journal Articles

Unexpected Association between Induction of Immunity to the Universal Tumor Antigen CYP1B1 and Response to Next Therapy

Free
John G. Gribben, David P. Ryan, Richard Boyajian, Robert G. Urban, Mary L. Hedley, Kathleen Beach, Patrick Nealon, Ursula Matulonis, Susana Campos, Timothy D. Gilligan, Paul G. Richardson, Blossom Marshall, Donna Neuberg, Lee M. Nadler
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (12): 4430–4436.
https://doi.org/10.1158/1078-0432.CCR-04-2111
Published: 15 June 2005
View articletitled, Unexpected Association between Induction of Immunity to the Universal Tumor Antigen CYP1B1 and Response to Next Therapy
Open the PDF for Unexpected Association between Induction of Immunity to the Universal Tumor Antigen CYP1B1 and Response to Next Therapy in another window